The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells.

Just as normal stem cells require niche cells for survival, leukemia-initiating cells (LICs) may also require niche cells for their maintenance. Chronic myeloid leukemia (CML) is caused by the activity of BCR-ABL, a constitutively active tyrosine kinase. CML therapy with tyrosine kinase inhibitors is highly effective; however, due to the persistence of residual LICs, it is not curative. Several factors are known to support CML LICs, but purification of LICs and a thorough understanding of their niche signals have not yet been achieved. Using a CML-like mouse model of myeloproliferative disease, we demonstrate that CML LICs can be divided into CD25(+)FcεRIα(-) Lineage marker (Lin)(-) Sca-1(+)c-Kit(+) (F(-)LSK) cells and CD25(-)F(-)LSK cells. The CD25(+)F(-)LSK cells had multilineage differentiation capacity, with a preference toward cytokine-producing mast cell commitment. Although cells interconverted between CD25(-)F(-)LSK and CD25(+)F(-)LSK status, the CD25(+)F(-)LSK cells exhibited higher LIC capacity. Our findings suggest that interleukin-2 derived from the microenvironment and CD25 expressed on CML LICs constitute a novel signaling axis. The high levels of CD25 expression in the CD34(+)CD38(-) fraction of human CML cells indicate that CD25(+) LICs constitute an "LIC-derived niche" that could be preferentially targeted in therapy for CML.

[1]  D. Voehringer.  Protective and pathological roles of mast cells and basophils , 2013, Nature Reviews Immunology.

[2]  B. Barton,et al.  Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML) , 2013, British journal of haematology.

[3]  M. Deininger,et al.  Pushing the limits of targeted therapy in chronic myeloid leukaemia , 2012, Nature Reviews Cancer.

[4]  O. Elemento,et al.  Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. , 2012, Cancer discovery.

[5]  M. Gönen,et al.  CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. , 2012, Blood.

[6]  J. Radich,et al.  IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. , 2011, Cancer cell.

[7]  B. Druker,et al.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.

[8]  Philippe Rousselot,et al.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.

[9]  C. Lassen,et al.  Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein , 2010, Proceedings of the National Academy of Sciences.

[10]  T. Phang,et al.  Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. , 2010, Cancer cell.

[11]  Yukio Kondo,et al.  TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia , 2010, Nature.

[12]  G. Schuurhuis,et al.  Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. , 2009, European journal of cancer.

[13]  R. Arceci.  PML targeting eradicates quiescent leukaemia-initiating cells , 2009 .

[14]  Yuankai Shi,et al.  Immunophenotypic study of basophils by multiparameter flow cytometry. , 2008, Archives of pathology & laboratory medicine.

[15]  T. Kitamura,et al.  Efficient retroviral transduction of human B-lymphoid and myeloid progenitors: marked inhibition of their growth by the Pax5 transgene , 2008, International journal of hematology.

[16]  T. Suda,et al.  Stem cell defects in ATM-deficient undifferentiated spermatogonia through DNA damage-induced cell-cycle arrest. , 2008, Cell stem cell.

[17]  M. Huber,et al.  IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells , 2007, Proceedings of the National Academy of Sciences.

[18]  Christine Tkaczyk,et al.  Integrated signalling pathways for mast-cell activation , 2006, Nature Reviews Immunology.

[19]  Hongyue Dai,et al.  Gene expression changes associated with progression and response in chronic myeloid leukemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Printz,et al.  CD25 Indicates the Neoplastic Phenotype of Mast Cells: A Novel Immunohistochemical Marker for the Diagnosis of Systemic Mastocytosis (SM) in Routinely Processed Bone Marrow Biopsy Specimens , 2004, The American journal of surgical pathology.

[21]  Keisuke Ito,et al.  Tie2/Angiopoietin-1 Signaling Regulates Hematopoietic Stem Cell Quiescence in the Bone Marrow Niche , 2004, Cell.

[22]  J. Melo,et al.  Chronic myeloid leukemia--advances in biology and new approaches to treatment. , 2003, The New England journal of medicine.

[23]  Toshiaki Kawakami,et al.  Regulation of mast-cell and basophil function and survival by IgE , 2002, Nature Reviews Immunology.

[24]  D. Neuberg,et al.  Expression of CD25 (interleukin-2 receptor α chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993 , 1997, Leukemia.

[25]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[26]  D. Neuberg,et al.  Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group/Medical Research Council. , 1997, Leukemia.

[27]  F. Alt,et al.  Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. , 1995, Immunity.

[28]  J. Darnell,et al.  Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. , 1995, Annual review of biochemistry.

[29]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[30]  T. Taniguchi,et al.  The IL-2 IL-2 receptor system: A current overview , 1993, Cell.

[31]  E. Gehan,et al.  Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. , 1985, Blood.